RxDoctor Payments Data

Karen Medzoyan, MD

Psychiatry · Lebanon, PANPI 1275534729

Payments from drug & device makers

$3,446in general payments, 2019–2025

Across 183 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$378
  • AbbVie$349
  • Takeda Pharmaceuticals U.S.A., Inc.$295
  • Ironshore Pharmaceuticals Inc.$290
  • Corium, LLC$289
  • Otsuka America Pharmaceutical, Inc.$269
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$3,39198%
  • Education$552%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,446 in reported general payments places this provider in the 85th percentile of 1,838 psychiatry providers in Pennsylvania.

See all psychiatry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$9,944
Medicare patients
15
Services billed
134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole33$45,093
VraylarCariprazine Hcl11$15,154
Adderall XrDextroamphetamine/Amphetamine12$4,799
Bupropion XlBupropion Hcl101$3,081
Aripiprazole49$1,829
Venlafaxine Hcl ErVenlafaxine Hcl80$1,355
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine11$884
Buspirone Hcl85$850
Escitalopram Oxalate52$646
Zolpidem Tartrate30$582
Fluoxetine Hcl43$434
Quetiapine Fumarate39$352
Trazodone Hcl63$330
Carbamazepine ErCarbamazepine12$321
Mirtazapine16$314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$269$45,09333 claims
AbbVieVraylar$349$15,15411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,838 psychiatry providers in Pennsylvania.

Other psychiatry in Lebanon

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →